Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | integrin beta subunit | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Loa Loa (eye worm) | integrin beta-2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | Integrin beta-3 precursor, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Echinococcus granulosus | integrin beta 2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Echinococcus multilocularis | integrin beta 2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Brugia malayi | Integrin beta pat-3 precursor | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | Integrin beta-PS precursor, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | ko:K06464 integrin beta 2, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | glutamate receptor kainate | 0.024 | 0.5223 | 1 |
Echinococcus multilocularis | NMDA receptor | 0.0172 | 0.2893 | 0.4368 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.026 | 0.5924 | 0.8946 |
Echinococcus multilocularis | glutamate receptor ionotropic kainate | 0.0172 | 0.2893 | 0.4368 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0128 | 0.1369 | 0.2067 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.026 | 0.5924 | 0.8946 |
Echinococcus granulosus | glutamate receptor 2 | 0.0128 | 0.1369 | 0.2067 |
Loa Loa (eye worm) | integrin beta-2 | 0.0378 | 1 | 1 |
Echinococcus granulosus | glutamate NMDA receptor subunit | 0.0107 | 0.0667 | 0.1007 |
Echinococcus granulosus | integrin beta 2 | 0.028 | 0.6622 | 1 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0107 | 0.0667 | 0.1007 |
Schistosoma mansoni | integrin beta subunit | 0.0223 | 0.4642 | 0.8725 |
Echinococcus multilocularis | integrin beta 2 | 0.028 | 0.6622 | 1 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.026 | 0.5924 | 0.8946 |
Echinococcus granulosus | glutamate receptor ionotrophic AMPA 3 | 0.0128 | 0.1369 | 0.2067 |
Schistosoma mansoni | glutamate receptor kainate | 0.024 | 0.5223 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.026 | 0.5924 | 0.8946 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0172 | 0.2893 | 0.4368 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.026 | 0.5924 | 0.8946 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0128 | 0.1369 | 0.154 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.026 | 0.5924 | 0.8946 |
Echinococcus granulosus | glutamate receptor ionotropic kainate 3 | 0.0172 | 0.2893 | 0.4368 |
Echinococcus granulosus | glutamate receptor ionotropic kainate | 0.0172 | 0.2893 | 0.4368 |
Echinococcus multilocularis | glutamate (NMDA) receptor subunit | 0.0107 | 0.0667 | 0.1007 |
Echinococcus multilocularis | glutamate receptor, ionotrophic, AMPA 3 | 0.0128 | 0.1369 | 0.2067 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.99 nM | Inihibition of human VCAM binding to VLA-4 of Ramos cells in ELISA | ChEMBL. | 11140722 |
IC50 (binding) | = 0.99 nM | Inihibition of human VCAM binding to VLA-4 of Ramos cells in ELISA | ChEMBL. | 11140722 |
IC50 (binding) | = 184 nM | Inhibition of human VCAM and Ramos cell VLA-4 interaction | ChEMBL. | 11140722 |
IC50 (binding) | = 184 nM | Inhibition of human VCAM and Ramos cell VLA-4 interaction | ChEMBL. | 11140722 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.